论文部分内容阅读
目的:根据胃癌术后病理Ki-67表达高低情况对比进展期胃癌患者预后、疾病进展时间。方法:临床选取100例胃癌术后患者,应用免疫组织化学法检测患者Ki-67的表达水平,判断患者的预后及疾病进展时间。结果:患者的Ki-67表达水平与临床病理分期呈正相关;ⅡB期患者的Ki-67表达水平(10.56±1.02)显著高于ⅡA组的(7.67±0.71);ⅢB期患者的Ki-67表达水平(20.56±1.41)显著高于ⅢA期的(12.62±1.32),差异有统计学意义(t=20.55,P<0.05),术后对患者进行随访,患者的1年、2年、3年生存率与临床分期呈负相关,差异均有统计学意义(P<0.05)。结论:Ki-67表达水平有利于胃癌的病理分期判断,有助于胃癌预后及疾病进展的进一步评估。
OBJECTIVE: To compare the prognosis of patients with advanced gastric cancer and the time to disease progression according to the pathological Ki-67 expression after operation. Methods: 100 patients with gastric cancer were selected clinically. The expression of Ki-67 was detected by immunohistochemistry and the prognosis and disease progression time were determined. Results Ki-67 expression was positively correlated with clinicopathological stage, Ki-67 expression in stage IIB was significantly higher than that in group IIA (10.57 ± 0.71), Ki-67 expression in stage IIIB (20.56 ± 1.41) was significantly higher than that of stage ⅢA (12.62 ± 1.32), the difference was statistically significant (t = 20.55, P <0.05). Patients were followed up for 1 year, 2 years and 3 years The survival rate was negatively correlated with clinical stage, the differences were statistically significant (P <0.05). Conclusion: The expression of Ki-67 is beneficial to the pathological staging of gastric cancer, which is helpful to the prognosis and progression of gastric cancer.